KR950032087A - N-(3-아미노프로필)-n-페닐-5,6,7,8-테트라히드로나프탈렌-2-카르복사미드 유도체, 이것의 제조방법 및 이것의 치료에의 이용 - Google Patents

N-(3-아미노프로필)-n-페닐-5,6,7,8-테트라히드로나프탈렌-2-카르복사미드 유도체, 이것의 제조방법 및 이것의 치료에의 이용 Download PDF

Info

Publication number
KR950032087A
KR950032087A KR1019950001834A KR19950001834A KR950032087A KR 950032087 A KR950032087 A KR 950032087A KR 1019950001834 A KR1019950001834 A KR 1019950001834A KR 19950001834 A KR19950001834 A KR 19950001834A KR 950032087 A KR950032087 A KR 950032087A
Authority
KR
South Korea
Prior art keywords
group
dihydro
inden
tetrahydronaphthalene
formula
Prior art date
Application number
KR1019950001834A
Other languages
English (en)
Other versions
KR100294727B1 (ko
Inventor
프로스트 죠나단
조르쥬 빠스칼
빠쏘 빠트릭
바르트쉬 레진느
루쎌 꼬린느
하워드 윌리엄스 폴
끌로드 뮐레 쟝
Original Assignee
에.뚜레 레메뜨르
신떼라보 소시에떼 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9401198A external-priority patent/FR2715652B1/fr
Priority claimed from FR9401199A external-priority patent/FR2715654B1/fr
Priority claimed from FR9401200A external-priority patent/FR2715658B1/fr
Application filed by 에.뚜레 레메뜨르, 신떼라보 소시에떼 아노님 filed Critical 에.뚜레 레메뜨르
Publication of KR950032087A publication Critical patent/KR950032087A/ko
Application granted granted Critical
Publication of KR100294727B1 publication Critical patent/KR100294727B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/88—Carboxylic acid amides having nitrogen atoms of carboxamide groups bound to an acyclic carbon atom and to a carbon atom of a six-membered aromatic ring wherein at least one ortho-hydrogen atom has been replaced
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

일반식 (Ⅰ)에 해당하는 화합물.
여기서, R1은 수소 또는 할로겐 원자 또는 메틸기 또는 C1-C4알콕시기를 나타내고, R1″은 수소 또는 할로겐 원자를 나타내고, R1″은 수소원자 또는 메톡시기를 나타내고, R3은 단독으로, C1-C3알킬기를 나타내고, R4는 2,3-디히드로-1H-인덴-2-일기, 2,3-디히드로-1H-인덴-1-일기 또는 l,2,3,4-테트라히드로나프탈렌-1-일를 나타내거나, 다르게는 R3과 R4는 질소원자와 함께 1,2,3,4-테트라히드로이소퀴놀-2-일기, 6,7-디메톡시-1,2,3,4-테트라히드로이소퀴놀-2-일, 5,8-디메톡시-1,2,3,4-테트라히드로이소퀴놀-2-일, 1,2,3,4-테트라히드로-9H-피리도〔3,4-b〕인돌-2-일, 1,2,3,4-테트라히드로-9H-피리도〔4,3-b〕인돌-3-일, 4,5,6.7-테트라히드로티에노〔2,3-c〕피리드-6-일, 2,3-디히드로-1H-이소인돌-2-일 또는 2,3,4,5-테트라히드로-1H-3-벤자제핀-3-일기를 형성한다.

Description

N-(3-아미노프로필)-N-페닐-5,6,7,8-테트라히드로나프탈렌-2-카르복사미드 유도체, 이것의 제조방법 및 이것의 치료에의 이용
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 염기 또는 산과 함께 부가염의 형태이고, 일반식(I)에 해당하며, 임의로 순수한 광학이성체 또는 이와 같은 이성체의 혼합물의 형태인 화합물.
    여기서, R1은 수소 또는 할로겐 원자, 메틸기 또는 C1-C4알콕시기를 나타내고, R1″은 수소 또는 할로겐 원자를 나타내고, R1″은 수소원자 또는 메톡시기를 나타내고, R3은 단독으로, C1-C3알킬기를 나타내고, R4는 단독으로 2,3-디히드로-1H-인덴-2-일기, 2,3-디히드로-1H-인덴-1-일기 또는 l,2,3,4-테트라히드로나프탈렌-1-일기를 나타내거나, 다르게는 R3과 R4는 그것들을 지니는 질소원자와 함께 1,2,3,4-테트라히드로이소퀴놀-2-일기, 6,7-디메톡시-1,2,3,4-테트라히드로이소퀴놀-2-일기, 5,8-디메톡시-1,2,3,4-테트라히드로이소퀴놀-2-일기, 1,2,3,4-테트라히드로-9H-피리도〔3,4-b〕인돌-2-일기, 1,2,3,4-테트라히드로-9H-피리도〔4,3-b〕인돌-3-일기, 4,5,6,7-테트라히드로티에노〔2,3-c〕피리드-6-일기, 2,3-디히드로-1H-이소인돌-2-일기 또는 2,3,4,5-테트라히드로-1H-3-벤자제핀-3-일기를 형성하고 이들의 각각의 화학식은 다음과 같으며 :
    단, R1이 알콕시, R1′과 R1″이 각각 수소, 그리고 R3과 R4가 질소원자와 함께 비치환된 또는 치환된 1,2,3,4-테트라히드로이소퀴놀리닐-2인 화합물은 제외한다.
  2. 제1항에 있어서, R1은 할로겐 원자를 나타내고, R1′은 수소 또는 할로겐 원자률 나타내고, R1″은 수소원자를 나타내고, R3은 단독으로 C1-C3알킬기를 나타내고, R4는 단독으로 2,3-디히드로-1H-인덴-2-일기, 2,3-디히드로-1H-인덴-1-일기 또는 1,2,3,4-테트라히드로나프탈렌-1-일기를 나타내거나, 다르게는 R3과 R4는 그것들을 지니는 질소원자와 함께 1,2,3,4-테트라히드로이소퀴놀-2-일기, 6,7- 디메톡시-1,2,3,4-테트라히드로이소퀴놀-2-일기 또는 5,8-디메톡시-1,2,3,4-테트라히드로이소퀴놀-2-일기를 형성하는 것을 특징으로 하는 화합물.
  3. 염기 또는 산과 함께 부가염의 형태인 N-〔3-〔2,3-디히드로-1H-인덴-2-일)메틸아미노〕프로필〕-N-(3,4-디클로로페닐)-5,6,7,8-테트라히드로나프탈렌-2-카르복사미드.
  4. 순수한 광학이성체 또는 이와 같은 이성체의 혼합물의 형태이고 염기 또는 산과 함께 부가염의 형태인 N-〔3-〔2,3-디히드로-1H-인덴-2-일)메틸아미노〕프로필〕-N-(3,4-디클로로페닐)-5,6,7,8, -테트라히드로나프탈렌-2-카르복사미드.
  5. 순수한 광학이성체 또는 이와 같은 이성체의 혼합물의 형태이고 염기 또는 산과 함께 부가염의 형태인 N-〔3-(1,2,3,4-테트라히드로나프탈렌-1-일)메틸아미노〕프로필〕-N-(3,4-디클로로페닐)-5, 6, 7, 8-테트라히드로나프탈렌-2-카르복사미드.
  6. 일반식(Ⅱ)
    (여기서, R1,R1′및 R1″은 제1항에 정의되어 있다)의 벤젠아민을 일반식(Ⅲ)
    의 5,6,7,8-테트라히드로나프탈렌-2-카르복실산메틸과 반응시켜 일반식(Ⅳ)
    의 아미드를 얻고 나서 식(Ⅴ)
    의 1-브로모-3-클로로-프로판과 반응시켜 일반식(Ⅵ)의 클로로 유도체를 얻고 나서 일반식 HNR3R4(여기서, R3과 R4는 제1항에 정의되어 있다)의 아민과 최종적으로 반응시키는 것을 특징으로 하는 제1항에 따른 화합물의 제조방법.
  7. 제1항 내지 제5항중의 어느 한 항에 따른 화합물로 이루어진 것을 특징으로 하는 의약.
  8. 부형제와 결합된 제1항 내지 제5항 중의 어느 한 항에 따른 화합물을 함유하는 것을 특징으로 하는 제약 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950001834A 1994-02-03 1995-02-02 N-(3-아미노프로필)-n-페닐-5,6,7,8-테트라히드로나프탈렌-2-카르복사미드유도체,이것의제조방법및이것의치료에의이용 KR100294727B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
FR94-01198 1994-02-03
FR9401198A FR2715652B1 (fr) 1994-02-03 1994-02-03 Dérivés de N-[3-[(2,3-dihydro-1H-inden-2-yl)alkyl-amino]propyl]-N-phényl-5,6,7,8-tétrahydronaphtalène-2-carboxamide leur préparation et leur application en thérapeutique.
FR94-01200 1994-02-03
FR94.1198 1994-02-03
FR94-01199 1994-02-03
FR9401199A FR2715654B1 (fr) 1994-02-03 1994-02-03 Dérivé de N-[3-(1,2,3,4-tétrahydroisoquinoléin-2-yl)-propyl]-N-phényl-5,6,7,8-tétrahydronaphtalène-2-carboxamide, leur préparation et leur application en thérapeutique.
FR94.1199 1994-02-03
FR94.1200 1994-02-03
FR9401200A FR2715658B1 (fr) 1994-02-03 1994-02-03 Dérivés de N-(3-aminopropyl)-N-phényl-5,6,7,8-tétrahydronaphtalène-2-carboxamide, leur préparation et leur application en thérapeutique.

Publications (2)

Publication Number Publication Date
KR950032087A true KR950032087A (ko) 1995-12-20
KR100294727B1 KR100294727B1 (ko) 2001-09-17

Family

ID=27252865

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950001834A KR100294727B1 (ko) 1994-02-03 1995-02-02 N-(3-아미노프로필)-n-페닐-5,6,7,8-테트라히드로나프탈렌-2-카르복사미드유도체,이것의제조방법및이것의치료에의이용

Country Status (25)

Country Link
US (2) US5550162A (ko)
EP (1) EP0666250B1 (ko)
JP (1) JPH07304717A (ko)
KR (1) KR100294727B1 (ko)
CN (1) CN1069309C (ko)
AT (1) ATE163178T1 (ko)
AU (1) AU680078B2 (ko)
CA (1) CA2141729A1 (ko)
CZ (1) CZ286703B6 (ko)
DE (1) DE69501596T2 (ko)
DK (1) DK0666250T3 (ko)
ES (1) ES2114277T3 (ko)
FI (1) FI950458A (ko)
GR (1) GR3026517T3 (ko)
HK (1) HK1005618A1 (ko)
HU (1) HU214870B (ko)
IL (1) IL112531A (ko)
NO (1) NO307825B1 (ko)
NZ (1) NZ270443A (ko)
PL (1) PL179247B1 (ko)
RU (1) RU2138479C1 (ko)
SI (1) SI0666250T1 (ko)
SK (1) SK280913B6 (ko)
TW (1) TW281667B (ko)
ZA (1) ZA95835B (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4308788A1 (de) * 1993-03-18 1994-09-22 Bayer Ag Hetero-tricyclisch-substituierte Phenyl-cyclohexan-carbonsäurederivate
US6008219A (en) * 1995-03-27 1999-12-28 Smithkline Beech P.L.C. Bicyclic amine derivatives and their use as anti-psychotic agents
CN1152055C (zh) 2001-03-20 2004-06-02 清华大学 磁性微球的表面包覆和基团功能化修饰方法及所得微球及其应用
NZ543100A (en) * 2003-04-17 2008-07-31 Toyama Chemical Co Ltd Preventive/remedy for retinal nerve dieases containing alkyl ether derivatives or salts thereof
US7846579B2 (en) 2005-03-25 2010-12-07 Victor Krasnov Thin film battery with protective packaging
US8865340B2 (en) 2011-10-20 2014-10-21 Front Edge Technology Inc. Thin film battery packaging formed by localized heating
US9887429B2 (en) 2011-12-21 2018-02-06 Front Edge Technology Inc. Laminated lithium battery
US8864954B2 (en) 2011-12-23 2014-10-21 Front Edge Technology Inc. Sputtering lithium-containing material with multiple targets
US9077000B2 (en) 2012-03-29 2015-07-07 Front Edge Technology, Inc. Thin film battery and localized heat treatment
US9257695B2 (en) 2012-03-29 2016-02-09 Front Edge Technology, Inc. Localized heat treatment of battery component films
US9159964B2 (en) 2012-09-25 2015-10-13 Front Edge Technology, Inc. Solid state battery having mismatched battery cells
US8753724B2 (en) 2012-09-26 2014-06-17 Front Edge Technology Inc. Plasma deposition on a partially formed battery through a mesh screen
US9356320B2 (en) 2012-10-15 2016-05-31 Front Edge Technology Inc. Lithium battery having low leakage anode
US10008739B2 (en) 2015-02-23 2018-06-26 Front Edge Technology, Inc. Solid-state lithium battery with electrolyte
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
PT3697785T (pt) 2017-10-18 2023-04-03 Jubilant Epipad LLC Compostos de imidazopiridina como inibidores de pad
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
PT3704120T (pt) 2017-11-24 2024-07-03 Jubilant Episcribe Llc Compostos heterocíclicos como inibidores de prmt5
BR112020018610A2 (pt) 2018-03-13 2020-12-29 Jubilant Prodel LLC Compostos de fórmula i, fórmula ii, fórmula iii, fórmula iv, fórmula v, fórmula vi, ou seus polimorfos, estereoisômeros, tautômeros, profármacos, solvatos e sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos; processo de preparação; composição farmacêutica; e método para o tratamento e/ou prevenção de várias doenças, que incluem câncer e doenças infecciosas
CN115521306B (zh) * 2022-09-26 2024-03-26 贵州大学 一种1,2,3,4-四氢-β-咔啉衍生物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3483206A (en) * 1967-12-15 1969-12-09 Ciba Geigy Corp N-isoquinolylalkanoyl-n-arylamines
DE3202100A1 (de) * 1982-01-23 1983-08-04 Basf Ag, 6700 Ludwigshafen Substituierte benzoesaeure-4-hydroxyanilide, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
DE3405329A1 (de) * 1984-02-15 1985-08-22 Sandoz-Patent-GmbH, 7850 Lörrach Neue allylaminderivate, verfahren zu ihrer herstellung und ihre verwendung
DE3418270A1 (de) * 1984-05-17 1985-11-21 Dr. Karl Thomae Gmbh, 7950 Biberach Neue aminotetralinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US4548293A (en) * 1984-07-13 1985-10-22 Brock Manufacturing, Inc. Bin ladder construction
GB8603765D0 (en) * 1986-02-15 1986-03-19 Beecham Wuelfung Gmbh & Co Kg Compounds
FR2618149B1 (fr) * 1987-07-16 1989-09-22 Synthelabo Derives de n-aminoalkyl n-phenyl arylamides, leur preparation et leur application en therapeutique
US5177089A (en) * 1988-06-01 1993-01-05 Eisai Co., Ltd. Butenoic or propenoic acid derivative
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
US5300523A (en) * 1988-07-28 1994-04-05 Bayer Aktiengesellschaft Substituted aminomethyltetralins and their heterocyclic analogues
FR2694557B1 (fr) * 1992-08-05 1994-09-23 Synthelabo Dérivés de tétrahydronaphtalène, leur préparation, et leur application en thérapeutique.

Also Published As

Publication number Publication date
ATE163178T1 (de) 1998-02-15
CA2141729A1 (en) 1995-08-04
SI0666250T1 (en) 1998-06-30
CZ286703B6 (en) 2000-06-14
IL112531A (en) 1999-03-12
IL112531A0 (en) 1995-05-26
NO950379L (no) 1995-08-04
ZA95835B (en) 1996-03-29
FI950458A0 (fi) 1995-02-02
JPH07304717A (ja) 1995-11-21
US5663183A (en) 1997-09-02
HUT73190A (en) 1996-06-28
GR3026517T3 (en) 1998-07-31
CN1069309C (zh) 2001-08-08
KR100294727B1 (ko) 2001-09-17
DE69501596T2 (de) 1998-09-10
US5550162A (en) 1996-08-27
NO307825B1 (no) 2000-06-05
CN1109870A (zh) 1995-10-11
AU680078B2 (en) 1997-07-17
SK12995A3 (en) 1995-08-09
NO950379D0 (no) 1995-02-02
CZ26995A3 (en) 1995-09-13
DE69501596D1 (de) 1998-03-19
EP0666250A1 (fr) 1995-08-09
PL179247B1 (pl) 2000-08-31
HU9500309D0 (en) 1995-03-28
SK280913B6 (sk) 2000-09-12
EP0666250B1 (fr) 1998-02-11
FI950458A (fi) 1995-08-04
RU2138479C1 (ru) 1999-09-27
TW281667B (ko) 1996-07-21
NZ270443A (en) 1996-02-27
ES2114277T3 (es) 1998-05-16
AU1154495A (en) 1995-08-10
RU95101375A (ru) 1996-11-20
PL307039A1 (en) 1995-08-07
HU214870B (hu) 1998-07-28
HK1005618A1 (en) 1999-01-15
DK0666250T3 (da) 1998-09-23

Similar Documents

Publication Publication Date Title
KR950032087A (ko) N-(3-아미노프로필)-n-페닐-5,6,7,8-테트라히드로나프탈렌-2-카르복사미드 유도체, 이것의 제조방법 및 이것의 치료에의 이용
KR880006247A (ko) 티에노피리디논 및 이의 제조방법
ATE280170T1 (de) Cyclopenta(b)(1,4) diazepino(6,7,1-hi)indole als 5ht2c antagonisten
EP0330065A1 (en) Sulfonamide compounds
CA2422703C (en) Process for the preparation of mesylates of piperazine derivatives
PT1669359E (pt) Processo para a preparação de olanzapina e um seu intermediário
KR950032184A (ko) 3-(2-아미노에틸)-4-[3-(트리플루오로메틸)벤조일]-3, 4-디히드로-2h-1, 4-벤즈옥사진 유도체, 그 제조방법 및 그 치료학적 적용
JP7431155B2 (ja) テトラヒドロナフチルウレア誘導体の製造方法
JPH03279361A (ja) ピペラジニルキノロン誘導体の製造方法
KR920006346A (ko) 3-(1h-인다졸-3-일)-4-피리딘아민, 이의 제조방법, 이의 제조를 위한 중간체 및 약제로서의 이의 용도
JP2010132701A (ja) 三環式化合物の調製において有用な中間体の合成
WO1996003364A1 (fr) Derive du benzoylethylene
HUP0003856A2 (hu) 6-Pirrolidin-2-ilpirindin-származékok, eljárás előállításukra és gyógyászati alkalmazásuk
WO2002057211A1 (en) Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use
TWI295988B (en) Method for the production of high purity enamines
AU646201B2 (en) A process for producing an aromatic compound by electrophilic reaction and aromatic compound derivatives
US4659826A (en) Synthesis of salicylamides with improved yield and purity
EP0539418A1 (en) Imidazopyridine paf antagonists
JPH0219368A (ja) アミノフェノール誘導体及びその製法
JPH03141252A (ja) １―アルコキシカルボニルチオ―１―ベンゾイル―２―（ｎ，ｎ―ジメチルアミノ）エテン誘導体およびその製造法
JPH02160776A (ja) チオフェンカルボキシアミド誘導体、その製造方法及び該化合物を含有する医薬組成物
AU2001249957A1 (en) Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-Ribose) glycohydrolase, and methods for their use
JPH0211590A (ja) ホスホン酸ジエステル誘導体
JPH0399079A (ja) インドリジン誘導体
FR2715654A1 (fr) Dérivé de N-[3-(1,2,3,4-tétrahydroisoquinoléin-2-yl)-propyl]-N-phényl-5,6,7,8-tétrahydronaphtalène-2-carboxamide, leur préparation et leur application en thérapeutique.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee